BREAST CANCER

Register Now

Testing & Image Analysis

+ Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer
Article-icon

This article compares the use of fluorescence in situ hybridization (FISH) and dual in situ hybridization (DISH) in the determination of HER2 amplification in breast cancer.


Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer

Aaron S. Mansfield, MD et al.

This article compares the use of fluorescence in situ hybridization (FISH) and dual in situ hybridization (DISH) in the determination of HER2 amplification in breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+ HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
Article-icon

This article examines the impact of HER2 heterogeneity on patient response to HER2-targeted therapy.


HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

Hee Jin Lee, MD et al.

This article examines the impact of HER2 heterogeneity on patient response to HER2-targeted therapy.
Register now to review full resource. Or, if you have registered, login now.

+ The Diagnostic Utility of the Minimal Carcinoma Triple Stain in Breast Carcinomas
Article-icon

This article examines the use of a multiplex, cocktail immunostain (CK7, p63, and E-cadherin) to aid in the diagnosis of small breast cancer tissue samples.


The Diagnostic Utility of the Minimal Carcinoma Triple Stain in Breast Carcinomas

Dara S. Ross, MD et al.

This article examines the use of a multiplex, cocktail immunostain (CK7, p63, and E-cadherin) to aid in the diagnosis of small breast cancer tissue samples.
Register now to review full resource. Or, if you have registered, login now.

+ CK5 Is More Sensitive Than CK5/6 in Identifying the “Basal-like” Phenotype of Breast Carcinoma
Article-icon

This article examines the use of CK5 vs. CK5/6 antibodies for the identification of basal-like carcinomas in breast cancer diagnosis.


CK5 Is More Sensitive Than CK5/6 in Identifying the “Basal-like” Phenotype of Breast Carcinoma

Rohit Bhargava, MD et al.

This article examines the use of CK5 vs. CK5/6 antibodies for the identification of basal-like carcinomas in breast cancer diagnosis..
Register now to review full resource. Or, if you have registered, login now.

+ Clinicopathologic Relevance of Claudin 5 Expression in Breast Cancer
Article-icon

This article examines the use of claudin 5 as a new biomarker predictive of recurrence in breast cancer.


Clinicopathologic Relevance of Claudin 5 Expression in Breast Cancer

Hitoshi Sugimoto, MD et al.

This article examines the use of claudin 5 as a new biomarker predictive of recurrence in breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+ Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues: A Useful Immunomarker for Breast and Urothelial Carcinomas
Article-icon

This article examines the use of GATA3 as a biomarker for determination of breast or urothelial cancer.


Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues: A Useful Immunomarker for Breast and Urothelial Carcinomas

Haiyan Liu, MD et al.

This article examines the use of GATA3 as a biomarker for determination of breast or urothelial cancer.
Register now to review full resource. Or, if you have registered, login now.

+ Expression of Lewis X Is Associated With Poor Prognosis in Triple-Negative Breast Cancer
Article-icon

This article examines the use of Lewis X antigen as a prognostic marker in triple-negative breast cancer.


Expression of Lewis X Is Associated With Poor Prognosis in Triple-Negative Breast Cancer

Young Wha Koh, MD et al.

This article examines the use of Lewis X antigen as a prognostic marker in triple-negative breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+ NY-BR-1 and PAX8 Immunoreactivity in Breast, Gynecologic Tract, and Other CK7+ Carcinomas: Potential Use for Determining Site of Origin
Article-icon

This article examines the use of NY-BR-1 and PAX8 as markers for distinguishing between a variety of breast and gynecologic carcinomas.


NY-BR-1 and PAX8 Immunoreactivity in Breast, Gynecologic Tract, and Other CK7+ Carcinomas: Potential Use for Determining Site of Origin

Anna H. Woodard, MD et al.

This article examines the use of NY-BR-1 and PAX8 as markers for distinguishing between a variety of breast and gynecologic carcinomas.
Register now to review full resource. Or, if you have registered, login now.

+ Breast Cancer Subtypes Predispose the Site of Distant Metastases
Article-icon

This article explores the relationship between clinicopathologic factors and sites of distant metastsis in patients with advanced breast cancer.


Breast Cancer Subtypes Predispose the Site of Distant Metastases

Abha Soni, DO, MPH et al.

This article explores the relationship between clinicopathologic factors and sites of distant metastsis in patients with advanced breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+False-Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions: Report of Three Cases and Review of the Literature
Article-icon

This article reviews 3 cases of lymph nodes with benign glandular inclusions and summarizes the pathologic features of benign glandular inclusions, including the histologic and immunohistochemical features that can be used to distinguish the benign inclusions from metastatic carcinoma.


False-Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions: Report of Three Cases and Review of the Literature

Yan Peng, MD, PhD et al.

This article reviews 3 cases of lymph nodes with benign glandular inclusions and summarizes the pathologic features of benign glandular inclusions, including the histologic and immunohistochemical features that can be used to distinguish the benign inclusions from metastatic carcinoma.
Register now to review full resource. Or, if you have registered, login now.

+Adenomyoepithelioma of the Breast
Article-icon

This article reviews a case study examining the clinical and pathologic features of breast adenomyoepithelioma, a rare benign breast neoplasm characterized by biphasic proliferation of epithelial and myoepithelial cells.


+Molecular Pathology of Breast Cancer: What a Pathologist Needs to Know
Article-icon

This article reviews the different subtypes of breast cancer and how molecular testing has changed and will continue to change breast cancer diagnosis.


Molecular Pathology of Breast Cancer: What a Pathologist Needs to Know

Kimberly H. Allison, MD

This article reviews the different subtypes of breast cancer and how molecular testing has changed and will continue to change breast cancer diagnosis.
Register now to review full resource. Or, if you have registered, login now.

+Existing, Evolving and Emerging Prognostic and Predictive Factors in Breast Carcinoma: Perspectives from a Pathologist-Oncologist Team
Article-icon

This multimedia course offers an overview of the most clinically relevant factors in determining the management of invasive breast carcinoma. Critical issues in the pathological determination of these factors are addressed by a breast pathologist, and their clinical applications are discussed by a medical oncologist specializing in managing patients with breast cancer.


Existing, Evolving and Emerging Prognostic and Predictive Factors in Breast Carcinoma: Perspectives from a Pathologist-Oncologist Team

Syed Amir Fazal Hoda, MD, FASCP and Anne Moore, MD

This multimedia course offers an overview of the most clinically relevant factors in determining the management of invasive breast carcinoma. Critical issues in the pathological determination of these factors are addressed by a breast pathologist, and their clinical applications are discussed by a medical oncologist specializing in managing patients with breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+Common Consultation Conundrums in Breast Pathology
Article-icon

This multimedia course provides pathologists with a practical approach to handling problematic breast lesions including papillary, fibroepithelial, columnar cell and in situ lesions, small glandular proliferations, among others.


Common Consultation Conundrums in Breast Pathology

Sandra J. Shin, MD, FASCP

This multimedia course provides pathologists with a practical approach to handling problematic breast lesions including papillary, fibroepithelial, columnar cell and in situ lesions, small glandular proliferations, among others.
Register now to review full resource. Or, if you have registered, login now.

+Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
Article-icon

This multimedia course reviews the “best practices” for pre-analytical and analytical processing of prognostic and predictive biomarker assessment in breast carcinomas, specifically reviewing issues applicable to ER/PR and HER2 IHC.


Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

Richard Walter Cartun, PhD

This multimedia course reviews the “best practices” for pre-analytical and analytical processing of prognostic and predictive biomarker assessment in breast carcinomas, specifically reviewing issues applicable to ER/PR and HER2 IHC. Topics covered include specimen collection, fixation and processing, as well as use of adequate controls and comparison of laboratory results with standard benchmarks.
Register now to review full resource. Or, if you have registered, login now.

+Recent Advances in Clinical Applications of Circulating Cell-free DNA Integrity
Article-icon

This review article provides an overview of circulating DNA as a biomarker in cancer and summarizes the recently reported assays for detecting circulating DNA.


Recent Advances in Clinical Applications of Circulating Cell-free DNA Integrity

Jiajia Yu, MD, Guohao Gu, MD and Shaoqing Ju, PhD

This review article provides an overview of circulating DNA as a biomarker in cancer and summarizes the recently reported assays for detecting circulating DNA.
Register now to review full resource. Or, if you have registered, login now.

+Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy
Article-icon

This review article provides an overview of the molecular subtypes of breast carcinoma, with a focus on the basal-like phenotype and a discussion of how transcriptomic analysis may lead to further subclassification of this subtype.


Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy

Rupninder Sandhu, MBBS et al.

This review article provides an overview of the molecular subtypes of breast carcinoma, with a focus on the basal-like phenotype and a discussion of how transcriptomic analysis may lead to further subclassification of this subtype.
Register now to review full resource. Or, if you have registered, login now.

+GATA3 Expression in Advanced Breast Cancer: Prognostic Value and Organ-Specific Relapse
Article-icon

The prognostic significance of GATA3 in breast cancer remains controversial. In this study, researchers assessed the prognostic value of the molecule in a subset of advanced breast cancers and control breast cancers (no metastasis after follow-up).


GATA3 Expression in Advanced Breast Cancer: Prognostic Value and Organ-Specific Relapse

Brandi C. McCleskey, MD et al.

The prognostic significance of GATA3 in breast cancer remains controversial. In this study, researchers assessed the prognostic value of the molecule in a subset of advanced breast cancers and control breast cancers (no metastasis after follow-up). Findings suggest that GATA3 may not act solely as a luminal differentiation marker, and further uncovering the molecular pathways by which GATA3 regulates the downstream targets will be crucial to our understanding of breast cancer dissemination.
Register now to review full resource. Or, if you have registered, login now.

+Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens
Article-icon

In this review, authors discuss the main advantages and disadvantages of the techniques developed so far for the evaluation of HER2 status in breast cancer specimens.


Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens

Daniela Furrer, MSc et al.

Reliable Human epidermal growth factor receptor 2 (HER2) evaluation is central to determining the eligibility of patients with breast cancer to targeted anti-HER2 therapies such as trastuzumab and lapatinib. Presently, several methods exist for the determination of HER2 status at different levels (protein, RNA, and DNA level). In this review, authors discuss the main advantages and disadvantages of the techniques developed so far for the evaluation of HER2 status in breast cancer specimens.
Register now to review full resource. Or, if you have registered, login now.

+Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
Article-icon

This article reviews a study of patients with HER2-positive breast cancer treated with surgery, adjuvant chemotherapy, and 1 year of trastuzumab.


Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab

Hee Jin Lee, MD, PhD et al.

This article reviews a study of patients with HER2-positive breast cancer treated with surgery, adjuvant chemotherapy, and 1 year of trastuzumab. Three areas that showed different levels of HER2 protein expression were chosen, and silver in situ hybridization was performed. Evaluation of intratumoral heterogeneity, especially in cases with hormone receptor positivity, may be valuable for assessing the prognosis of HER2-positive patients anticipating treatment with adjuvant systemic therapy and trastuzumab.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: LCIS vs. ALH
Article-icon

This micro-course reviews the features of Lobular Neoplasia. Jensen then uses case challenges to provide insight into the distinctions of LCIS vs. ALH.


Lobular Neoplasia: LCIS vs. ALH

Kristen Jensen, MD

This micro-course reviews the features of Lobular Neoplasia. Jensen then uses case challenges to provide insight into the distinctions of LCIS vs. ALH. Diagnostic aids and images demonstrate the architecture, features, mimics, and stakes of each. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Incidental Lobular Neoplasia
Article-icon

A case challenge in this micro-course provides insight into the distinctions Incidental of Lobular Neoplasia.


Incidental Lobular Neoplasia

Kristen Jensen, MD

A case challenge in this micro-course provides insight into the distinctions Incidental of Lobular Neoplasia. Diagnostic aids and images demonstrate the architecture, features, mimics, and stakes. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: Mircoinvasion
Article-icon

This micro-course focuses on recogizing microinvasion in Lobular Neoplasia in situ from diagnostic aids and images.


Lobular Neoplasia: Mircoinvasion

Kristen Jensen, MD

This micro-course focuses on recogizing microinvasion in Lobular Neoplasia in situ from diagnostic aids and images. You'll review a challenging case as well as architecture, features, mimics, and stakes. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: Pleomorphic LCIS
Article-icon

This micro-course focuses on recognizing Pleomorphic LCIS from diagnostic aids and images.


Lobular Neoplasia: Pleomorphic LCIS

Kristen Jensen, MD

This micro-course focuses on recognizing Pleomorphic LCIS from diagnostic aids and images. Jensen reviews a challenging case and reviews architecture, features, mimics, and stakes. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: Subtle Invasive Carcinomas
Article-icon

This micro-course focuses on recogizing subtle invasive lesions of Lobular Neoplasia from diagnostic aids and images.


Lobular Neoplasia: Subtle Invasive Carcinomas

Kristen Jensen, MD

This micro-course focuses on recogizing subtle invasive lesions of Lobular Neoplasia from diagnostic aids and images. Jensen reviews a challenging case and reviews architecture, features, mimics, and stakes. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: Invasive Carcinoma Mimics
Article-icon

This micro-course provides a closer look at several of the morphologic variants that can occur in Lobular Neoplasia in situ and Invasive Lobular Neoplasia.


Lobular Neoplasia: Invasive Carcinoma Mimics

Kristen Jensen, MD

This micro-course provides a closer look at several of the morphologic variants that can occur in Lobular Neoplasia in situ and Invasive Lobular Neoplasia. Jensen reviews cases that include a variety of images and diagnostic aid revealing their architecture, features and stakes. Treatment discussions are also covered.
Register now to review full resource. Or, if you have registered, login now.

+Lobular Neoplasia: Use of E-cadherin for Diagnosis
Article-icon

This micro-course describes the pros and cons of using E-cadherin stains in the diagnosis of intraductal and invasive proliferations of Lobular Neoplasia.


Lobular Neoplasia: Use of E-cadherin for Diagnosis

Kristen Jensen, MD

This micro-course describes the pros and cons of using E-cadherin stains in the diagnosis of intraductal and invasive proliferations of Lobular Neoplasia. Jensen discusses instances where E-cadherin may be helpful and when to avoid it. Several case images provide a closer look at cases of DCIS and LCIS.
Register now to review full resource. Or, if you have registered, login now.

+A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma
Article-icon

This article reviews the clinicopathologic features, treatment, and outcomes of patients with MBC treated at an institution.


A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma

Ashley Cimino-Mathews, MD, Sangita Verma, MD, et al.

Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. This article reviews the clinicopathologic features, treatment, and outcomes of patients with MBC treated at an institution. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection
Article-icon

This study aimed to identify the rate of HER2 discordance in this cohort of cases.


Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection

Susan Prendeville MB, FRCPath et al.

The updated American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (2013) for human epidermal growth factor receptor 2 (HER2) testing in breast cancer recommend repeat testing at excision of HER2-negative grade 3 breast tumors. This study aimed to identify the rate of HER2 discordance in this cohort of cases. Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+Utility of Estrogen Receptor, Progesterone Receptor, and HER-2/neu Analysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma
Article-icon

This article reviews a study to determine the frequency of estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (HER2) testing multiple foci of ipsilateral invasive breast carcinoma at our institution and to evaluate resulting change in treatment.


Utility of Estrogen Receptor, Progesterone Receptor, and HER-2/neu Analysis of Multiple Foci in Multifocal Ipsilateral Invasive Breast Carcinoma

Ellen G. East MD et al.

This article reviews a study to determine the frequency of estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (HER2) testing multiple foci of ipsilateral invasive breast carcinoma at our institution and to evaluate resulting change in treatment . Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

+The Minimal Carcinoma Triple Stain Is Superior to Commercially Available Multiplex Immunohistochemical Stains Breast Triple Stain and LC/DC Breast Cocktail
Article-icon

The Minimal Carcinoma (MC) Triple Stain is a tri-chromogen multiplex immunostain (CK7, p63, and E-cadherin) helpful in classifying morphologically ambiguous and/or small carcinomas as either ductal or lobular and/or in situ or invasive.


The Minimal Carcinoma Triple Stain Is Superior to Commercially Available Multiplex Immunohistochemical Stains Breast Triple Stain and LC/DC Breast Cocktail

Paula S. Ginter MD et al.

The Minimal Carcinoma (MC) Triple Stain is a tri-chromogen multiplex immunostain (CK7, p63, and E-cadherin) helpful in classifying morphologically ambiguous and/or small carcinomas as either ductal or lobular and/or in situ or invasive. Resarchers compared the utility of this stain with two commercially available duplex/multiplex immunostains: Breast Triple Stain (BTS) (Clarient, Aliso Viejo, CA; CK5, p63, and CK8/18) and LC/DC Breast Cocktail (LCDC) (Biocare, Concord, CA; E-cadherin and p120). Note: ASCP Membership is required to login and review this resource.
Register now to review full resource. Or, if you have registered, login now.

 
+PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Article-icon

PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.


PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Cimino-Mathews A, Thompson E, et al

PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 testing by Fluorescence In Situ Hybridization- Experience of an Academic Consultation Practice
Article-icon

Defines 5 FISH groups. Although the status of 95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of the other 5% (groups 2-4) conflict with previous HER2 gene amplification status and with HER2 status by immunohistochemistry.


Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 testing by Fluorescence In Situ Hybridization- Experience of an Academic Consultation Practice

Press MF et al

Defines 5 FISH groups. Although the status of 95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of the other 5% (groups 2-4) conflict with previous HER2 gene amplification status and with HER2 status by immunohistochemistry.
Register now to review full resource. Or, if you have registered, login now.

+PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

Cimino-Mathews A, Thompson E, et al

PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 testing by Fluorescence In Situ Hybridization- Experience of an Academic Consultation Practice

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 testing by Fluorescence In Situ Hybridization- Experience of an Academic Consultation Practice

Press MF et al

Defines 5 FISH groups. Although the status of 95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of the other 5% (groups 2-4) conflict with previous HER2 gene amplification status and with HER2 status by immunohistochemistry.
Register now to review full resource. Or, if you have registered, login now.

+Papilloma vs. Papillary Carcinoma
Article-icon

This multimedia mini course discusses the historical perspective of tumors of the breast, differences between papilloma and papillary carcinoma, histology of breast, papilloma and myoepithelial cells, and central and peripheral papillomas.


Papilloma vs. Papillary Carcinoma

Syed A. Hoda, M.D.

TThis multimedia mini course discusses the historical perspective of tumors of the breast, differences between papilloma and papillary carcinoma, histology of breast, papilloma and myoepithelial cells, and central and peripheral papillomas.
Register now to review full resource. Or, if you have registered, login now.

+Papilloma Myoepithelial Cells
Article-icon

This multimedia module discusses myoepithelial cells present in leison and perimeter, WHO Guidelines, intraductal papilloma + DCIS.


Papilloma Myoepithelial Cells

Syed A. Hoda, M.D.

This multimedia module discusses myoepithelial cells present in leison and perimeter, WHO Guidelines, intraductal papilloma + DCIS.
Register now to review full resource. Or, if you have registered, login now.

+Papilloma + DCIS
Article-icon

This multimedia module discusses implication of papilloma with atypia, papilloma risk for invasive carcinoma, challenging papillary case, and intraductal papillary carcinoma.


Papilloma + DCIS

Syed A. Hoda, M.D.

This multimedia module discusses implication of papilloma with atypia, papilloma risk for invasive carcinoma, challenging papillary case, and intraductal papillary carcinoma.
Register now to review full resource. Or, if you have registered, login now.

+Intracystic CA, Encrysted CA, and Encapsulated CA
Article-icon

This multimedia module discusses intracystic carcinoma, encysted carcinoma, encapsulated carcinoma, a challenging papillary case and WHO guidelines and descriptions.


Intracystic CA, Encrysted CA, and Encapsulated CA

Syed A. Hoda, M.D.

This multimedia module discusses intracystic carcinoma, encysted carcinoma, encapsulated carcinoma, a challenging papillary case and WHO guidelines and descriptions.
Register now to review full resource. Or, if you have registered, login now.

+Solid and Invasive Papillary CA
Article-icon

This multimedia case discusses challenging papillary cases, solid papillary carcinoma, invasive papillary carcinoma and the WHO description.


Solid and Invasive Papillary CA

Syed A. Hoda, M.D.

This multimedia case discusses challenging papillary cases, solid papillary carcinoma, invasive papillary carcinoma and the WHO description.
Register now to review full resource. Or, if you have registered, login now.

+Challenging Papillary Cases
Article-icon

This multimedia case discusses challenging papillary cases, the evolution of adenomyoepithelioma, the evolution of carcinoma in adenomyoepithelioma, and the tall cell papillary thyroid-like carcinoma.


Challenging Papillary Cases

Syed A. Hoda, M.D.

This multimedia case discusses challenging papillary cases, the evolution of adenomyoepithelioma, the evolution of carcinoma in adenomyoepithelioma, and the tall cell papillary thyroid-like carcinoma.
Register now to review full resource. Or, if you have registered, login now.

+Challenging & Problematic Cases
Article-icon

This multimedia case discusses challenging papillary cases, invasive papillary carcinoma, metastatic ovarian carcinoma to breast, problematic consultation cases, and myoepithelial cells in mammary papillary lesions.


Challenging & Problematic Cases

Syed A. Hoda, M.D.

This multimedia case discusses challenging papillary cases, invasive papillary carcinoma, metastatic ovarian carcinoma to breast, problematic consultation cases, and myoepithelial cells in mammary papillary lesions.
Register now to review full resource. Or, if you have registered, login now.

+Molecular Subtypes of Breast Cancer
Article-icon

This multimedia short course will explain the molecular classification of breast cancer.


Molecular Subtypes of Breast Cancer

Mamatha Chivukula, MD, FASCP

This multimedia short course will explain the molecular classification of breast cancer.
Register now to review full resource. Or, if you have registered, login now.

+Ancillary Molecular Testing
Article-icon

This multimedia mini course will describe ancillary molecular testing for breast cancer and discuss the role of the pathologist in personalized medicine.


Ancillary Molecular Testing

Mamatha Chivukula, MD, FASCP

This multimedia mini course will describe ancillary molecular testing for breast cancer and discuss the role of the pathologist in personalized medicine.
Register now to review full resource. Or, if you have registered, login now.

+Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer
Article-icon

This article compares the use of fluorescence in situ hybridization (FISH) and dual in situ hybridization (DISH) in the determination of HER2 amplification in breast cancer.


Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer

Aaron S. Mansfield, MD, William R. Sukov, MD, Jeanette E. Eckel-Passow, PhD, et al.

This article compares the use of fluorescence in situ hybridization (FISH) and dual in situ hybridization (DISH) in the determination of HER2 amplification in breast cancer.
Register now to review full resource. Or, if you have registered, login now.

This website is sponsored by:

 Founding Sponsor

Copyright © 2017. The American Society for Clinical Pathology. All rights reserved.